Ultragenyx Pharmaceutical Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €1.95B +42.0% €546.66M +237.2% 28.0% +0.16 pp N/A N/A
    (estimated) €1.37B +35.3% €162.13M -272.3% 11.8% +0.21 pp N/A N/A
    (estimated) €1.02B +47.6% -€94.08M -72.6% -9.3% +0.41 pp €258.44M -36.2% 25.5% -0.33 pp
    (estimated) €687.68M +22.6% -€343.21M -20.7% -49.9% +0.27 pp €405.15M +50.3% 58.9% +0.11 pp
    (estimated) €561.04M +17.4% -€433.03M -10.8% -77.2% +0.24 pp €269.53M -177.7% 48.0% +1.2 pp
    €477.85M +29.0% -€485.49M -6.2% -101.6% +0.38 pp -€346.89M -5.0% -72.6% +0.26 pp
    €370.39M +19.5% -€517.43M -14.2% -139.7% +0.55 pp -€365.10M +82.7% -98.6% -0.34 pp
    €309.90M +3.4% -€603.40M +55.8% -194.7% -0.66 pp -€199.88M -11.8% -64.5% +0.11 pp
    €299.73M +29.7% -€387.26M +143.4% -129.2% -0.60 pp -€226.55M +200.7% -75.6% -0.43 pp
    €231.18M +161.3% -€159.13M -53.7% -68.8% +3.2 pp -€75.33M -72.4% -32.6% +2.8 pp
    €88.46M +101.4% -€343.51M +103.8% -388.3% -0.046 pp -€273.41M +11.9% -309.1% +2.5 pp
    €43.92M +1,871.5% -€168.55M -34.6% -383.7% +110 pp -€244.36M +14.1% -556.3% +91 pp
    €2.23M +1,863.9% -€257.71M +22.9% -11,567.3% +1.7K pp -€214.13M +66.5% -9,611.4% +1.0K pp
    €113.44K +∞% -€209.72M +68.8% -184,867.7% -1.8K pp -€128.61M +49.3% -113,373.7% -1.1K pp
    €0.00 +NaN% -€124.21M +143.5% N/A -€86.17M +137.8% N/A
    €0.00 +NaN% -€51.01M +70.5% N/A -€36.24M +38.0% N/A
    €0.00 +NaN% -€29.91M +114.7% N/A -€26.26M +169.8% N/A
    €0.00 +NaN% -€13.93M +138.5% N/A -€9.73M +116.3% N/A
    €0.00 -€5.84M N/A -€4.50M N/A

    Notifications